

RNS Number: 9484B

Cross Shore Acquisition Corporation  
13 August 2007

Cross Shore Acquisition Corporation

13 August 2007

THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF IRELAND, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

#### Result of Special General Meeting

Cross Shore announces that it has adjourned the Special General Meeting convened for 10 August 2007 at which, inter alia, Cross Shore Shareholders were to be asked to vote on a resolution to approve the acquisition of ReSearch Pharmaceutical Services Inc. ('Acquisition').

As of 10 August 2007, the company had received sufficient votes against the Acquisition that the resolution was unlikely to be approved if put to the shareholders at the Special General Meeting. In addition, as of 10 August 2007, approximately 35.4 million warrants had been tendered for exchange pursuant to the tender offer. This amount reflects an increase of approximately 11.4 million warrants from the amount tendered as of 8 August 2007 but remains 0.2% less than the 95% required to be tendered as a condition to the Acquisition. Under the terms of the Merger Agreement, this condition is waivable. The completion of the warrant tender offer also remains conditional on completion of the Acquisition and absent completion of the Acquisition, the warrants will not convert into shares and will remain as warrants. Pending satisfaction of the conditions of the Merger Agreement, either party is entitled to terminate the Merger Agreement on written notice to the other.

As announced on 3 August 2007, Cross Shore had received expressions of interest from third party institutional investors who indicated their interest in acquiring a significant number of shares and warrants which, if acquired, voted, and tendered respectively, may allow the transaction to proceed. Discussions have been ongoing with one of those institutional investors and the Board of Directors reasonably believes that it is possible to reach a definitive agreement shortly to allow the transaction to proceed.

Consequently the Board has decided to extend the adjournment of the Special General Meeting until a time to be determined in the immediate near future to allow additional time to enter into such definitive agreement and tabulate revised proxies.

The adjourned meeting will take place as before at the offices of McDermott, Will & Emery, 227 West Monroe Street, Chicago, Illinois 60606. Proxies already deposited in respect of the Special General Meeting will remain valid for the adjourned meeting, however, if a shareholder wishes to change their vote, they should either request and complete a new proxy form or attend the meeting in person. A new deadline for the return of proxies will be notified at the same time as the date for the adjourned meeting.

#### ENQUIRIES:

Cross Shore +1 843 597 4760  
Dennis Smith

Arbuthnot Securities Limited +44 207 012 2000  
Nominated Adviser  
James Steel / Guy Blakeney

This announcement does not constitute, or form part of, an offer or an invitation to purchase any securities.

This announcement is not for distribution into the United States, Canada, Japan, Australia, the Republic of Ireland or the Republic of South Africa or any other jurisdiction where its distribution would constitute a violation of the relevant laws of such jurisdiction. Neither Cross Shore Shares nor the Cross Shore Warrants have been registered under the United States Securities Act of 1933, as amended, or under the applicable securities laws Canada, Japan, Australia, the Republic of Ireland or the Republic of South Africa. Accordingly (subject to certain exceptions), neither the Cross Shore Shares nor the Cross Shore Warrants may, directly or indirectly, be offered or sold within the United States, Canada, Japan, Australia, the Republic of Ireland or the Republic of South Africa or to or by any national, resident or citizen of such countries. The distribution of the Readmission Document in other jurisdictions may be restricted by law and therefore persons into whose possession the Readmission Document comes should inform themselves about and observe any such restrictions.

Any failure to comply with these restrictions may constitute a violation of the securities law of any such jurisdictions.

Arbuthnot Securities Limited, which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting as nominated adviser and UK broker to the Company in connection with Re-admission. Its responsibilities as the Company's nominated adviser under the AIM Rules are owed solely to the London Stock Exchange and are not owed to the Company or to any Director or Proposed Director or to any other person.

Arbuthnot Securities Limited is acting exclusively for the Company and for no one else and will not be responsible to anyone other than the Company for providing the protections afforded to their clients or for providing advice in relation to the contents of this announcement or the Re-admission. No representation or warranty, express or implied, is made by Arbuthnot Securities Limited as to the contents of this announcement. The information contained in this announcement is not intended to inform or be relied upon by any subsequent purchasers of Cross Shore Shares or Warrants (whether on or off exchange) and accordingly no duty of care is accepted in relation to them.

The Directors and Proposed Directors of Cross Shore Acquisition Corporation accept responsibility, individually and collectively, for the information contained in this announcement and for compliance with the AIM Rules. To the best of the knowledge and belief of the Directors and Proposed Directors, who have taken all reasonable care to ensure that such is the case, the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

END

This information is provided by RNS  
The company news service from the London Stock Exchange

END  
STRBCGDI I GBGGRD

SUBJECT: GEN  
COMPANY: CSE USU1549T1098